When compared to cisplatin therapy alone, the combination of FAM120A depletion with cisplatin significantly diminished the tumor growth index in GC (Fig. 7e), indicating that FAM120A depletion enhanced sensitivity to cisplatin in vivo. This evidence concerns the gene FAM120A and gastric cancer.